Samsung Biologics logo

Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 liters at its manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds a total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Content by Samsung Biologics

Exterior view of the Samsung Biologics campus building in Songdo, South Korea, headquarters of the CDMO's global biomanufacturing network.
| 3 min read
Industry Perspectives
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Researcher examining a multiwell plate alongside cell culture dishes in a laboratory.
Skip RNA purification for faster RT-qPCR workflows
Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.
Webinars
Thermo Fisher Scientific
Abstract rainbow-colored beams of light spreading across a dark background.
How to choose the right fluorochromes for complex flow cytometry panels
Compare fluorochromes based on resolution, spillover, antigen expression, and other factors that can affect panel performance.
Whitepaper
BD Bio
Illustration of multiple glowing blue and purple spherical cells against a dark blue background.
Technology Guide: High-content analysis in modern drug discovery
As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.
Technology Guides
Yokogawa